Jean-Pierre Sommadossi
CIK 1296995 · President, CEO, and Chairman · last filed 2026-02-03
Jean-Pierre Sommadossi is a President, CEO, and Chairman who has filed 22 SEC Form 4 insider transactions across 3 companies since 2007. The most recent filing, for AVIR, was dated Feb 3, 2026. Across all open-market trades the lifetime net is −$457.0K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $26.0M across reported positions. 1 Form 144 notice of planned sales is also on file; the latest, for AVIR on Feb 1, 2024, lists the filer as an officer and director.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AVIR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
225 FRANKLIN STREET SUITE 2100
BOSTON, MA 02110
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AVIR | President, CEO, and Chairman | 6,633,855 | $3.92 | $26.04M | -$457.0K | 9 | 2026-02-03 |
| Kezar Life Sciences, Inc. (KZR) Delisted | Director | 17,844 | $7.29 | $130.1K | $0 | 4 | 2021-06-30 |
| IDENIX PHARMACEUTICALS INC (IDIX) Delisted | President, CEO, Chairman | 2,219,754 | — | — | $0 | 7 | 2010-02-11 |
Holdings By Holder
| Symbol | Holder | Shares | Share of Total | Reported |
|---|---|---|---|---|
| AVIR | Direct | 767,830 | 11.6% | 2026-02-03 |
| Held by JPM Partners LLC | 5,866,025 | 88.4% | 2026-02-03 | |
| Total | 6,633,855 | |||
| KZR | By JPM Partners, LLC | 17,844 | 100.0% | 2018-06-27 |
| Total | 17,844 | |||
| IDIX | Direct | 2,058,569 | 92.7% | 2008-09-17 |
| Jean-Pierre Sommadossi 1998 Irrevocable Trust By Trust |
161,185 | 7.3% | 2008-09-17 | |
| Total | 2,219,754 |
Recent Filings
22 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-03 | AVIR | Mixed | +466,890 | -$77.8K | EDGAR |
| 2025-02-04 | AVIR | Mixed | +184,383 | -$271.1K | EDGAR |
| 2024-09-19 | AVIR | Sell (S)10b5-1 | −57,969 | -$234.2K | EDGAR |
| 2024-06-07 | AVIR | Sell (S)10b5-1 | −1,006 | -$4.0K | EDGAR |
| 2024-02-02 | AVIR | Mixed10b5-1 Plan adopted May 18, 2023 |
+116,557 | -$218.8K | EDGAR |
| 2024-02-01 | AVIR | Notice (144) Officer, Director · Planned Feb 1, 2024 · 10b5-1 plan Sold: Form 4 filed Feb 2, 2024 |
−65,476 | -$266.5K | EDGAR |
| 2023-03-03 | — | Disp (D) | — | $0 | |
| 2023-02-02 | AVIR | Grant (A) | — | $0 | EDGAR |
| 2022-02-02 | AVIR | Grant (A) | — | $0 | EDGAR |
| 2021-06-30 | Kezar Life Sciences, Inc. (KZR) Delisted | Grant (A) | — | $0 | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).